Please login to the form below

gemcitabine

This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.

Keytruda monotherapy fails in triple negative breast cancer

By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine). ... One such study is Keynote-355, which looks

Latest news

Celgene’s Abraxane fails pancreatic cancer trial

Expectations for a positive outcome for the trial weren’t high, particularly as it used gemcitabine as a control. ... Since APACT was started, a new regimen called mFOLFIRINOX – based on oxaliplatin, leucovorin, irinotecan, and fluorouracil – has
CTI slumps as Servier-partnered lymphoma drug fails

gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint.
NICE knocks-back Shire's pancreatic cancer drug Onivyde

The watchdog was reviewing the treatment’s use in England and Wales for metastatic pancreatic cancer that has progressed after gemcitabine-based therapy.
Ipsen buys cancer business from stripped down Merrimack

For the tens of thousands of patients living with pancreatic cancer in the US who have received prior treatment with gemcitabine, Onivyde represents an important, differentiated innovation, given its proven overall
Shire wins EU licence for pancreatic cancer drug Onivyde

treatment with Lilly's Gemzar (gemcitabine).

More from news
Approximately 1 fully matching, plus 48 partially matching documents found.

Latest Intelligence

The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Battling breast cancer with precision medicine (Part 2)

I wanted her to access the best treatment possible. I also knew that carboplatin was especially effective when used with another chemotherapy called gemcitabine, as the two drugs are known to ... tested the PARP inhibitor with the gemcitabine-carboplatin
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

Unfortunately, recurrence rates in high-grade ovarian cancer mean that platinum resistance is a very real possibility, leaving second-line treatment such as gemcitabine, topotecan or liposomal doxorubicin less effective over
Marketing strategy in complex environments

cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages apoptosis of cell

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director, Healthcare Communications: Salary TBC

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Account Director – UK Office: Excellent salary and benefits

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Subscribe to our email news alerts

PMHub

Add my company

IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...